Cigna Corporation
NYSE:CIMedical - Healthcare Plans
-$4.44 today
- Market cap
- $75.20B
- Beta
- 0.30
- P/E (TTM)
- 11.7
- EPS (TTM)
- $23.95
- Dividend yield
- 2.19%
Volume 2.49M
Average 1.61M
CI Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cigna CorporationNYSE: CI
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables turns negative
Q3 FY2026 accounts payables was -$334M, compared with $163M a year earlier. Trailing-twelve-month accounts payables was $3.55B. Over 3 fiscal years it compounded at +17.3% a year.
Context
- Accounts payables amounted to 1.0% of revenue in FY2025, up 0.6 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near -$334M or moves back toward the trailing-twelve-month quarterly average of $887.5M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 2.8B USD
- Year-over-year change
- +145.8%
- 4-year CAGR
- +8.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.8B | +145.8% |
| FY2024 | 2024-12-31 | 1.14B | -67.3% |
| FY2023 | 2023-12-31 | 3.48B | +100.7% |
| FY2022 | 2022-12-31 | 1.73B | -14.9% |
| FY2021 | 2021-12-31 | 2.04B | — |
Accounts Payables vs competitors
How CI compares with its peers on the latest reported figures
- CI's LTM Sep 2026 accounts payables of $3.55B is the 3rd largest of the 9 companies compared; the peer median is $34.13M.
- Its year-over-year change of +304.3% is the 2nd highest of 9, against a peer median of -70.4%.
- Accounts payables amounts to 1.2% of revenue for CI, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.37B | +332.8% | — | 3.3% | |
| LTM Sep 2026 | $6.18B | -183.6% | — | 1.4% | |
| LTM Sep 2026 | $3.55B | +304.3% | +17.3% | 1.2% | |
| LTM Sep 2026 | $1.02B | -400.6% | — | 0.5% | |
| LTM Jun 2026 | $947M | -80.8% | -3.3% | 0.2% | |
| LTM Sep 2026 | $121M | -88.3% | — | 0.1% | |
| LTM Jun 2026 | $74.49M | -60.0% | -15.7% | 0.5% | |
| LTM Sep 2026 | $62M | +231.9% | — | 0.1% | |
| LTM Mar 2026 | $6.26M | +69.2% | — | 0.1% | |
| Peer median (excluding CI) | $34.13M | -70.4% | -9.5% | 0.4% | |
Competitors are the stored peer set for CI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.42B | 6.78B | 5.37B | 3.78B | 6.29B |
| Depreciation & Amortization | 2.92B | 2.94B | 3.04B | 2.78B | 2.78B |
| Deferred Income Tax | (216M) | (472M) | (1.66B) | (95M) | 326M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (879M) | 259M | 3.03B | 418M | (261M) |
| Accounts Receivables | (3.5B) | (2.24B) | (1.66B) | (7.37B) | (4.63B) |
| Inventory | (557M) | (1.06B) | (868M) | (1.03B) | (646M) |
| Accounts Payables | 2.04B | 1.73B | 3.48B | 1.14B | 2.8B |
| Other Working Capital | 1.14B | 1.82B | 2.08B | 7.68B | 2.22B |
| Other Non-Cash Items | (57M) | (850M) | 2.04B | 3.49B | 473M |
| Operating Cash Flow | 7.19B | 8.66B | 11.81B | 10.36B | 9.6B |
| Capital Expenditures | (1.15B) | (1.3B) | (1.57B) | (1.41B) | (1.21B) |
| Acquisitions (Net) | (1.89B) | 4.84B | (434M) | 390M | 2.39B |
| Purchases of Investments | (6.11B) | (4.32B) | (5.54B) | (2.7B) | (7.2B) |
| Sales of Investments | 5.59B | 4.11B | 2.64B | 2.45B | 2.65B |
| Other Investing Activities | (50M) | (233M) | (264M) | (838M) | (1.03B) |
| Investing Cash Flow | (3.61B) | 3.1B | (5.17B) | (2.1B) | (4.41B) |
| Debt Repayment | 657M | (2.56B) | (278M) | 1.06B | (666M) |
| Common Stock Issued | 326M | 389M | 187M | 305M | 203M |
| Common Stock Repurchased | (7.74B) | (7.61B) | (2.28B) | (7.03B) | (3.62B) |
| Dividends Paid | (1.34B) | (1.38B) | (1.45B) | (1.57B) | (1.61B) |
| Other Financing Activities | (112M) | (79M) | (469M) | (411M) | (726M) |
| Financing Cash Flow | (8.21B) | (11.24B) | (4.29B) | (7.65B) | (6.42B) |
| Effect of Forex Changes | (65M) | (86M) | 16M | (20M) | 1.35B |
| Net Change in Cash | (4.7B) | 428M | 2.36B | 594M | 126M |
| Free Cash Flow | 6.04B | 7.36B | 10.24B | 8.96B | 8.39B |
Cigna Corporation
NYSE:CI
Intrinsic Alpha fair value
Locked
Current Price
$285.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.